Looking for more information on the ongoing ADAPT Phase 3 clinical trial in MG? Click here.

ABDEG™

ABDEG™ technology exploits the known mechanism by which antibodies are cleared from the systemic circulation. Specific mutations in the antibody Fc region alter the binding and clearance via the neonatal Fc receptor (FcRn) expressed on endothelial, hematopoietic and epithelial cells.

We are exploring ABDEG™-based products with several therapeutic applications:

  • ARGX-113: ARGX-113 is a first-in-class antibody fragment designed to bind FcRn, blocking IgG recycling (including the disease causing autoantibodies) and increasing IgG clearance. This results in a faster disease remission and drastically reduces the length and seriousness of acute autoimmune acute crisis.
  • Activation of  therapeutic antibody-mediated target clearance (‘sweeping antibodies’)

Nat Biotechnol 2005, Vaccaro et al.